Funding for this research was provided by:
Kementerian Kesihatan Malaysia
Received: 4 October 2018
Accepted: 20 May 2019
First Online: 14 June 2019
: All procedures and experimental protocols involving the use of NPC PDXs in this study were in accordance with the ethical standards of and approved by the Animal Care and Use Committee (ACUC), Ministry of Health, Malaysia [(ACUC/KKM/02 (03/2013), (05/2016), (16/2016) and (03/2017)]. The use of human blood specimens in this study was approved by the Medical Research and Ethics Committee (MREC), Ministry of Health, Malaysia [reference number: KKM/NIHSEC/P18–1062(10)]. Informed consent was obtained from all participating human subjects.
: Not applicable.
: SYT, MFCM, MM, NAA, TLC, MA, ASBK are co-inventors of a patent filed related to the contents of this manuscript. (Khoo ASB, Norazlin AA, Teow SY, Mohd Firdaus CM, Marini M, Chu TL, Munirah A. Isolated nasopharyngeal carcinoma cells and derivatives prepared thereof. Malaysian Patent PI 2018702497 filed July 17, 2018 (Patent Pending).